Boston, March 06, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in hybrid care enablement, is attending HIMSS 2024, March 11-15, in Orlando, Fla. Company leaders will be in booth #1441 to discuss Amwell’s hybrid care enablement platform, Virtual Nursing solution, automated care and behavioral health programs and how this technology can address workforce shortages, access to care, the mental health crisis and other industry challenges.
In addition, three Amwell clients will present during two sessions at HIMSS:
Tuesday, March 12
Wednesday, March 13
For more information about Amwell at HIMSS, or to talk with a company leader during the event, contact This email address is being protected from spambots. You need JavaScript enabled to view it..
About Amwell
Amwell provides a leading hybrid care enablement platform in the United States and globally, connecting and enabling providers, payers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that hybrid care delivery will transform healthcare. The company offers a single, comprehensive platform to support all digital health needs, from urgent to acute and post-acute care, as well as chronic care management and healthy living. With nearly two decades of experience, Amwell powers the digital care of more than 50 health plans, which collectively represent more than 100 million covered lives and many of the nation’s largest health systems. For more information, please visit https://business.amwell.com/.
©2024 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, ConvergeTM, CarepointTM and the Amwell Logo are registered trademarks or trademarks of American Well Corporation.
Last Trade: | US$7.87 |
Daily Change: | 0.03 0.38 |
Daily Volume: | 77,920 |
Market Cap: | US$107.580M |
December 18, 2024 October 30, 2024 October 08, 2024 July 31, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB